advertisement

WGA Rescources

Klearman M 20

Showing records 1 to 20 | Display all abstracts from Klearman M

70859 Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis
Wilson JC
Seminars in Arthritis & Rheumatism 2017; 46: 819-827
70534 Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis
Wilson JC
Seminars in Arthritis & Rheumatism 2017; 46: 650-656
70859 Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis
Sarsour K
Seminars in Arthritis & Rheumatism 2017; 46: 819-827
70534 Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis
Sarsour K
Seminars in Arthritis & Rheumatism 2017; 46: 650-656
70859 Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis
Collinson N
Seminars in Arthritis & Rheumatism 2017; 46: 819-827
70534 Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis
Collinson N
Seminars in Arthritis & Rheumatism 2017; 46: 650-656
70859 Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis
Tuckwell K
Seminars in Arthritis & Rheumatism 2017; 46: 819-827
70534 Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis
Tuckwell K
Seminars in Arthritis & Rheumatism 2017; 46: 650-656
70859 Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis
Musselman D
Seminars in Arthritis & Rheumatism 2017; 46: 819-827
70534 Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis
Musselman D
Seminars in Arthritis & Rheumatism 2017; 46: 650-656
70859 Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis
Klearman M
Seminars in Arthritis & Rheumatism 2017; 46: 819-827
70534 Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis
Klearman M
Seminars in Arthritis & Rheumatism 2017; 46: 650-656
70859 Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis
Napalkov P
Seminars in Arthritis & Rheumatism 2017; 46: 819-827
70534 Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis
Napalkov P
Seminars in Arthritis & Rheumatism 2017; 46: 650-656
70859 Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis
Jick SS
Seminars in Arthritis & Rheumatism 2017; 46: 819-827
70534 Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis
Jick SS
Seminars in Arthritis & Rheumatism 2017; 46: 650-656
70859 Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis
Stone JH
Seminars in Arthritis & Rheumatism 2017; 46: 819-827
70534 Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis
Stone JH
Seminars in Arthritis & Rheumatism 2017; 46: 650-656
70859 Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis
Meier CR
Seminars in Arthritis & Rheumatism 2017; 46: 819-827
70534 Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis
Meier CR
Seminars in Arthritis & Rheumatism 2017; 46: 650-656

Issue 18-2

Change Issue


advertisement

Oculus